EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality

Mariangeli Monero-Paredes, Ednalise Santiago, Kelvin Carrasquillo-Carrion iD, Jessicca Y Renta, Igor B Rogozin iD, Abiel Roche-Lima iD, Jorge Duconge iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mariangeli Monero-Paredes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA. Hauptthemen laut MEDLINE: Aryldialkylphosphatase, Biomarkers, Clopidogrel, Hispanic or Latino. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIMHD NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clopidogrel, a prescription drug to reduce ischemic events in cardiovascular patients, has been extensively studied in mostly European individuals but not among Caribbean Hispanics. This study evaluated the low abundance and reduced activity of paraoxonase-1 (PON1) in clopidogrel-resistant patients as a predictive risk biomarker of poor responders and disease severity in this population. Thirty-six patients on clopidogrel (cases divided into poor and normal responders) were enrolled, along with 11 cardiovascular patients with no clopidogrel indications (positive control) and 13 healthy volunteers (negative control). Residual on-treatment platelet reactivity unit (PRU), PON1 abundance by Western blotting, and PON1 activity by enzymatic assays were measured. PON1 genotyping and computational haplotype phasing were performed on 512 DNA specimens for two genetic loci (rs662 and rs854560). No statistical differences in mean relative PON1 abundance were found among the groups (p > 0.05). However, a significantly lower enzymatic activity was found in poor responders (10.57 ± 6.79 µU/mL) when compared to controls (22.66 ± 8.30 µU/mL and 22.21 ± 9.66 µU/mL; p = 0.004). PON1 activity among carriers of the most prevalent PON1 haplotype (AA|AA) was significantly lower than in wild types (7.90 µU/mL vs. 22.03 µU/mL; p = 0.005). Our findings suggested that PON1 is a potential biomarker of cardiovascular disease severity in Caribbean Hispanics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AryldialkylphosphataseBiomarkersClopidogrelHispanic or LatinoAgedFemaleHumansMaleMiddle AgedCardiovascular DiseasesHaplotypesPlatelet Aggregation InhibitorsPolymorphism, Single NucleotideCaribbean People

Stichwörter der Autor:innen

Caribbean HispanicsPON1cardiovascular diseasesclopidogrelresistance

Substanzen

AryldialkylphosphataseBiomarkersClopidogrelPlatelet Aggregation InhibitorsPON1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.
  • Research Centers in Minority Institutions (RCMI) Program, Center for Collaborative Research in Health Disparities (CCRHD), University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.
  • Computational Biology Branch, National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), National Institutes of Health (NIH), Rockville Pike MSC 3830, Bethesda, MD 20894, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.

ORCID-Profile: Kelvin Carrasquillo-Carrion, Igor B Rogozin, Abiel Roche-Lima, Jorge Duconge

Förderung

  • NIGMS NIH HHS
  • NIMHD NIH HHS
  • NIH HHS
  • National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health
  • National Institute of General Medical Sciences (NIGMS)
  • European Union

Zitieren

APA

Monero-Paredes, M., Santiago, E., Carrasquillo-Carrion, K., Renta, J. Y., Rogozin, I. B., Roche-Lima, A., & Duconge, J. (2024). Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910657

Vancouver

Monero-Paredes M, Santiago E, Carrasquillo-Carrion K, Renta JY, Rogozin IB, Roche-Lima A, et al. Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910657

BibTeX
@article{MoneroParedes2024,
  author = {Monero-Paredes, Mariangeli and Santiago, Ednalise and Carrasquillo-Carrion, Kelvin and Renta, Jessicca Y and Rogozin, Igor B and Roche-Lima, Abiel and Duconge, Jorge},
  title = {Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910657}
}
Kostenlos starten →